ClinicalTrials.Veeva

Menu

Association Between Preoperative HALP and Immediate Postoperative Outcomes

C

Chitwan Medical College

Status

Completed

Conditions

Mortality
Lymphocytes
Hemoglobins
Platelets
Albumins
Morbidity
Whipples Procedure

Treatments

Other: pantients undergoing pancreaticoduodenectomy

Study type

Observational

Funder types

Other

Identifiers

NCT05506748
078/079-103

Details and patient eligibility

About

Multiple inflammation-based prognostic scores have been developed for the prediction of perioperative morbidity and mortality following pancreaticoduodenectomy (PD). Preoperative "Hemoglobin, Albumin, Lymphocytes and Platelets index (HALP)" is one of the promising inflammatory markers that has emerged as a predictor of postoperative survival. To date, no study has been done with preoperative HALP to predict 30days morbidity and mortality.

Is there any association between Preoperative HALP (hemoglobin, albumin, lymphocyte, and platelet) and 30 days post operative morbidity and mortality in patients undergoing Pancreaticoduodenectomy?

Full description

General Objective:

To assess the association between preoperative HALP and immediate postoperative outcome among patients undergoing PD.

Specific Objectives:

  1. To identify the magnitude of immediate post-operative morbidity and mortality in patients undergoing PD.
  2. To evaluate the descriptive measurement of preoperative Hemoglobin, Albumin, Lymphocytes, Platelets and HALP among patients undergoing PD.
  3. To compare the preoperative HALP with morbidity and mortality among patients undergoing PD.

Operational Definition:

  1. Immediate postoperative time - was taken as 30days following surgery.
  2. Morbidity- was defined by Clavién-Dindo20 grading for the surgical complication and DGE,21 POPF,22 and PPH23 -according to International Study Group of Pancreatic Surgery (ISGPS) grading.
  3. Mortality- survival within 30days.
  4. Level of preoperative HALP- normality test was done via SPSS and data of HALP followed normal Gaussian distribution. So, mean was used for the calculation of cut off value as 35.83. And, patients were divided into low HALP (≤35.83) group and high HALP (>35.83) group respectively

Enrollment

22 patients

Sex

All

Ages

15 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. All the cases of elective pancreaticoduodenectomies for malignant pancreatic head disease

Exclusion criteria

  1. Incomplete clinicopathological and follow-up data,
  2. Age <15 years and age >80 years
  3. History of antitumor treatments, and
  4. Record of other malignant tumors, (unresectable?)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems